We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,271

Biosimilar Approvals in the US and Canada - the ‘Patent Dance’
  • Bereskin & Parr LLP
  • Canada, USA
  • December 30 2015

The US and Canada each provide an abbreviated pathway (or shortcut) for a biosimilar manufacturer to get a product approved. The shortcut allows for a


Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer


Federal Court of Appeal clarifies test for double-patenting
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • May 12 2016

On April 20, 2016, the Federal Court of Appeal issued its decision in Mylan Pharmaceuticals ULC v Eli Lilly Canada Inc, 2016 FCA 119, a case relating


Federal Court continues to breathe life into motions to dismiss proceedings under the Patented Medicines (Notice of Compliance) Regulations
  • Osler Hoskin & Harcourt LLP
  • Canada
  • June 7 2016

In amended reasons released on May 26, 2016, the Federal Court in Janssen Inc. v. Celltrion Healthcare Co. Ltd. (Janssen) granted a motion to


Janssen awarded damages almost 10 years after Teva found to have infringed LEVAQUIN patent
  • Gowling WLG
  • Canada
  • June 24 2016

In a recent decision of the Federal Court (Janssen Inc. v. Teva Canada Limited, 2016 FC 593), Justice Hughes awarded approximately $18 million in


Patent is not found to be a selection patent, and thus was anticipated and obvious
  • Borden Ladner Gervais LLP
  • Canada
  • November 23 2015

The Federal Court has dismissed an application for prohibition to prevent the Minister of Health from issuing an NOC to Mylan for cinacalcet


Obviousness central to Federal Court’s REYATAZ (atazanavir bisulfate) decision
  • Gowling WLG
  • Canada
  • June 24 2016

In a decision dated May 27, 2016 in respect of Bristol-Myers Squibb’s (“BMS”) REYATAZ (atazanavir bisulfate), Justice Mactavish of the Federal


Developing a Patent Family Bigger than the Brady Bunch
  • Bereskin & Parr LLP
  • Canada
  • June 2 2016

New drugs require a huge amount of innovation, time, capital and risk to get to market. Nobody should begrudge a drug company for seeking strong


Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a


Federal Court dismisses prohibition application for quetiapine tablets SEROQUEL XR
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 20 2013

AstraZeneca Canada Inc. and AstraZeneca UK Limited (“AstraZeneca”) brought an application pursuant to section 6 of the Patented Medicines (Notice of